Acute Myeloid Leukemia Clinical Trial

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Summary

This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).

The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy.

The expansion (Part B), will further evaluate the safety and efficacy of CC-96191 administered at or below the MTD in one or more expansion cohorts in order to determine the RP2D.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants must satisfy the following criteria to be enrolled in the study:

1. Participant must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessments/procedures being conducted.

3. Participant is ≥ 18 years of age at the time of signing the ICF. 4. Relapsed or refractory CD33 positive AML at last visit as defined by the World Health Organization (WHO) Classification who have failed or who are ineligible for or have refused all available therapies for AML which may provide clinical benefit.

6. Participant has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

7. At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion without conditioning.

8. Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and during the safety follow-up period.

Exclusion Criteria:

The presence of any of the following will exclude a Participant from enrollment:

Participant is suspected or proven to have acute promyelocytic leukemia (FAB M3) based on morphology, immunophenotype, molecular assay, or karyotype.
Participant has received systemic anticancer therapy (including investigational therapy) or radiotherapy < 28 days or 5 half-lives, whichever is shorter, prior to the start of study treatment. Hydroxyurea is allowed to control peripheral leukemia blasts.
Participants with prior autologous hematopoietic stem cell transplant who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (eg, transplant-related side effects).
Prior allogeneic HSCT with either standard or reduced intensity conditioning ≤ 6 months prior to dosing.
Participants on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of topical steroids for ongoing skin or ocular GVHD is permitted.
Participant has persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to < Grade 2.
Participant has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening.
History of concurrent second cancers requiring active, ongoing systemic treatment.
Participant is known seropositive or active infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus or hepatitis C virus.
Impaired cardiac function or clinically significant cardiac diseases, as defined in the protocol .
Participant is a pregnant or lactating female.

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

70

Study ID:

NCT04789655

Recruitment Status:

Recruiting

Sponsor:

Celgene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 14 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35233, United States
University of Alabama at Birmingham
Birmingham Alabama, 35233, United States More Info
Pankit Vachhani, Site 109
Contact
Mayo Clinic - Jacksonville
Jacksonville Florida, 32224, United States
Winship Cancer Institute of Emory University
Atlanta Georgia, 30322, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Mayo Clinic
Rochester Minnesota, 55905, United States More Info
Mithun Shah, Site 110
Contact
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Jaime Koprivnikar, Site 101
Contact
Mt. Sinai Medical Center Division of Hematology/Oncology
New York New York, 10029, United States
Mt. Sinai Medical Center Division of Hematology/Oncology
New York New York, 10029, United States More Info
John Mascarenhas, Site 102
Contact
212-241-1948
The University of Texas - MD Anderson Cancer Center
Houston Texas, 77030, United States
Swedish Cancer Institute
Seattle Washington, 98109, United States
Tom Baker Cancer Center
Calgary Alberta, T2N 4, Canada
Princess Margaret Hospital University Health Network
Toronto Ontario, M5G 2, Canada
Institut Paoli Calmette Hematologie
Marseille cedex , 13273, France
Hopital Saint Louis
Paris , 75010, France
Local Institution - 304
Paris , 75010, France More Info
Site 304
Contact
Hopital Haut Leveque
Pessac Cedex , 33604, France
Local Institution - 301
Pessac Cedex , 33604, France More Info
Site 301
Contact
Gustave Roussy
Villejuif CEDEX , 94805, France

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

70

Study ID:

NCT04789655

Recruitment Status:

Recruiting

Sponsor:


Celgene

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.